Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
Board Member and Director, Africa Fighting Malaria (United States and South Africa), 2000-present
Fellow, 2000-present; Founder and Director, Environmental Unit, 1993-2003, Institute of Economic Affairs
Fellow, 2003; Director, 2001-2003, International Policy Network
Founder, Frederick Bastiat International Journalism Prize, 2001
Cofounder and Director, European Science and Environment Forum, 1995-2001
Research Analyst, Warburg Securities and Charles Stanley & Co., 1986-89
Ph.D., economics; MPhil., land economy, University of Cambridge
MSc., environmental and resource management, University College, London University
There is a growing cause for alarm as evidence of corner-cutting mounts-particularly among Indian generics manufacturers-and the products that are actually sold on the market don't maintain the same quality standards as those that received approval. Only time will tell how lethal the consequences of this corner cutting will be.
At this event, Dinesh Thakur will discuss his experiences and the wider problems of Indian drug quality. Pharmaceutical and medical experts will then discuss Thakur’s remarks and the safety of US and international drugs.
Indian companies exported generic drugs worth $4.2 billion to the United States last year, and demand is accelerating. But so too are safety concerns about these medicines -- and they’re not being addressed by the Indian government.
Tanzanian authorities and INTERPOL have just made a major seizure of fake and substandard drugs. While good news, it's a stark reminder that Africa remains ground zero in the global war on bad medicine.
Greens have failed to get wholesale political change on climate issues, but lots of small scale policies such as energy conservation building codes have been enacted over the years that more reasoned environmentalists can claim credit for.
Free trade zones possess many attributes of capitalist economies and can attract foreign companies, foreign investment in domestic companies, industrial production, and wealth generation. However, such zones are also troubling; they can produce several negative results including a strong mafia presence, massive counterfeit operations, tax evasion, money laundering, and even terror financing.
Evidence is mounting that some pharmaceutical manufacturers in countries like India cut corners and send low-quality products to major, developed markets. Worse still, they may have separate production lines for drugs they sell in developing markets like Africa, where poor quality is more likely to go unnoticed.
Free trade zones can become havens for smugglers, money launderers and terrorists in search of hard currency. And these problems can discredit free trade and regulatory reform by equating the free-for-all of cowboy capitalism with free markets.